Initiate research programs for translational bioinformatics and network pharmacology to support rational drug repositioning and combination therapy from discovery through clinical development.
Identification of at least 6 existing drugs suitable for repurposing and/or combination therapy for AD and ADRD prevention or treatment. The drugs selected for repurposing or combination therapy will be prioritized based on:
evidence that they modulate disease relevant pathways/networks gained from computational and empirical approaches.
preclinical proof-of-efficacy in a relevant model system.
availability of biomarkers to monitor target engagement in humans.
sufficient evidence of safety for the intended target population.
- Research Implementation Area
- Drug Repurposing and Combination Therapy Development
- PAR-17-032: Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01)
Research Programs and Resources
- Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease